TY  - JOUR
T1  - FDa requires black box warnings on labeling for botulinum toxin products
AU  - Kuehn BM
Y1  - 2009/06/10
N1  - 10.1001/jama.2009.780
JO  - JAMA
SP  - 2316
EP  - 2316
VL  - 301
IS  - 22
N2  - 
The FDA is also requiring Allergan Inc, which sells Botox and Botox Cosmetic (botulinum toxin type A); Solstice Neurosciences Inc, which sells Myobloc (botulinum toxin type B); and Ipsen Biopharm Ltd, maker of the recently FDA-approved Dysport (abobotulinumtoxinA), to develop risk-management strategies plans to prevent such adverse events. Additionally, the agency is requiring clinicians to provide a medication guide outlining botulismlike risks to patients treated with the drug or to their caregivers.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.780
UR  - http://dx.doi.org/10.1001/jama.2009.780
ER  -